Subgroup analysis |
Number of studies |
Number of estimates |
Pooled OR
(95% CI), I2 statistics (%), P-value for the
heterogeneity Q test |
Model used |
Congennital malformations |
|
|
|
|
Neuraminidase inhibitor |
7 |
8 |
0.9 (0.72 - 1.12);
I2 = 0%, P = 0.852 |
Fixed effects |
Oseltamivir |
6 |
6 |
0.89 (0.69 - 1.14); I2 = 0%, P
= 0.745 |
Fixed effects |
Heart malformations |
2 |
2 |
1.11 (0.61 - 2.03); I2 =
0%, P = 0.405 |
Fixed effects |
Low birth weight |
|
|
|
|
Neuraminidase inhibitor |
6 |
8 |
0.79 (0.68 - 0.92);
I2 = 0%, P = 0.483 |
Fixed effects |
Oseltamivir |
5 |
6 |
0.84 (0.71 - 0.99); I2 = 16.2%,
P = 0.309 |
Fixed effects |
Low Apgar score |
|
|
|
|
Neuraminidase inhibitor |
5 |
6 |
0.96 (0.77 - 1.2);
I2 = 0%, P = 0.643 |
Fixed effects |
Oseltamivir |
4 |
5 |
0.96 (0.77 - 1.2); I2 = 0%, P =
0.643 |
Fixed effects |
SGA |
|
|
|
|
Neuraminidase inhibitor |
4 |
6 |
0.78 (0.69 - 0.88);
I2 = 0%, P = 0.701 |
Fixed effects |
Oseltamivir |
4 |
6 |
0.77 (0.68 - 0.88); I2 = 0%, P
= 0.53 |
Fixed effects |
Preterm birth |
|
|
|
|
Neuraminidase inhibitor |
|
|
0.99 (0.89 - 1.09); I2 =
0%, P = 0.54 |
Fixed effects |
Oseltamivir |
7 |
9 |
1.03 (0.93 - 1.15); I2 = 0%, P
= 0.447 |
Fixed effects |